Novartis journeys to Mecca for Saudi vax effort

A Swiss-Saudi partnership has resulted in the opening of a vaccine plant in the holy city of Mecca. Novartis ($NVS) will provide vaccine manufacturing know-how to Arab Company for Pharmaceutical Products (Arabio), which owns the plant. Initial capacity will be 16 million doses per year when operation begins early next year, rising to 35 million vaccines. There's irony in the plant's location: vax-conscious Saudis request that haj pilgrims carry a certificate proving they've been vaccinated. Article

Sponsored By Digital Pharma Europe

Fierce Pharma Marketing is excited to announce the first virtual Digital Pharma Europe!

This summit will profile best-in-class case studies and senior-level discussions from leaders who are innovating the way we look at the intersection of digital technologies and marketing in Europe.